Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06008379
Other study ID # 7MW3711-2023-CP102
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 28, 2023
Est. completion date January 30, 2026

Study information

Verified date September 2023
Source Mabwell (Shanghai) Bioscience Co., Ltd.
Contact Sun Lu, Doctor
Phone 021-22200000*3121
Email shun-lu@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

7MW3711 is a antibody-drug conjugate(ADC) drected to a target wildly expressed on solid tumors. This is an open-label, multicenter, phase 1/2 study to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in subjects with advanced solid tumors.


Description:

Two parts are included in this study. The part of dose escalation and dose expansion(part 1) will enrolled subjects with advanced solid tumors and is to evaluate the safety and tolerability and to determine the maximum tolerated dose and/or the recommend pahse 2 dose(RP2D) of 7MW3711 in subjects with advanced solid tumors. The part of cohort expansion(part 2) will enrolled subejcts with selected advanced solid tumors and is to assess the preliminary efficacy of 7MW3711 in selected advanced solid tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 164
Est. completion date January 30, 2026
Est. primary completion date August 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. - Life expectancy of at least 3 months as assessed by the Investigator. - Part 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor, progressive after last treatment received and who progressed on or after standard therapies or intolerant to approved therapies or who lack of effient standard therapies; part 2: Histologically or cytologically confirmed locally advanced or metastatic selected advanced solid tumors having progressed after at least one line of standard systermic therapy or intolerate standard therapies. - An archival tumor tissue sample(formalin-fixed paraffin-embedded (FFPE) tumor tissue block or at least 5 unstained slides) or a fresh tissue sample should be provided. If the tissue sample cannot be provided during dose escalation, enrollment into the study is allowed after discussion with the Investigator - Measurable or evaluable disease by RECIST v1.1. - Have adequate hematopoietic, renal and hepatic functions. - Men or women willing to use adequate contraceptive measures throughout the study Exclusion Criteria: - Have other prior malignancies within 3 years before the first administration. - Known central nervous system metastatic disease or carcinomatous meningitis except for treated and stable brain metastases. - Have significant, uncontrolled, or active cardiovascular disease. - Known history of COPD, or intestinal lung disease, or other respiratory diseases requring inpatient treatments within 4 weeks prior to first administration. - Have adverse events due to prior antitumor therapy not resolved to grade 1 or lower by NCI CTCAE V5.0. - have active infections requiring treatment within 14 weeks; have infection of HIV, active infection of HCV and HBV. - Prior treatment with an antibody drug conjugate (ADC) that consists of an topoisomerase I inhibitor. - Prior treatment with B7-H3 targeted agents. - have received chemotherapy, immunotherapy, curative radiation within 3 weeks prior to the first administration or targeted molecular within 2 weeks prior to first administration. have received Chinese patent medicine or Chinese herbs of anti-tumor indications within 1 weeks prior to the first administration. - Have received any systemic immunosuppressants within 2 weeks prior to the first administration except for topical corticosteroids. - Have received any other investigational drugs or medical device within 4 weeks prior to the first administration. - History of drug abuse including narcotic and psychiatric drugs within 12 months prior to screening. - Pregnant, or nursing females

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
7MW3711 for injection
IV administration of 7MW3711, Q3W, 3 weeks a cycle
7MW3711 for injection
IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1

Locations

Country Name City State
China Hunan Cancer Hospital Changsha Hunan
China Zhejiang Cancer Hospital Hangzhou Zhejiang
China The Lung Cancer Center of Shanghai Chest Hospital Shanghai Shanghai
China Xuzhou Central Hospital Xuzhou Jiangsu
China Henan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Mabwell (Shanghai) Bioscience Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluation of the incidence of adverse events (AEs) (part 1) Incidence and seriousness of adverse events (AEs) and serious adverse events (SAEs) by CTCAE version 5.0. approximately up to 16 cycles, 21 days a cycle
Primary Identification of the MTD and /or RP2D of 7MW3711(part 1) from Day1 to Day21 in cycle1 of part 1
Primary Overall response rate (ORR) evaluated by investigators based on RECIST version 1.1 in selected solid tumors. (part 2) ORR:defined as the proportion of patients who achieved a best overall response of completeresponse (CR) or partial response (PR) approximately up to 2 years
Secondary evaluation of PK parameters of 7MW3711 Maximum observed concentration(Cmax) approximately up to 2 years
Secondary evaluation of PK parameters of 7MW3711 the time to Cmax(tmax) approximately up to 2 years
Secondary evaluation of PK parameters of 7MW3711 half-live(t1/2) approximately up to 2 years
Secondary evaluation of PK parameters of 7MW3711 Area under the concentration-time curve(AUC) approximately up to 2 years
Secondary overall response rate (ORR) (part1) ORR:defined as the proportion of patients who achieved a best overall response of completeresponse (CR) or partial response (PR) based on RECIST version 1.1. approximately up to 1 years
Secondary disease control rate(DCR) DCR:defined as the proportion of subjects with CR, PR, and SD based on RECIST 1.1 criteria approximately up to 2 years
Secondary progression-free survival(PFS) PFS:defined as time from the date of first administration to the date of first documented disease progression based on RECIST 1.1 criteria, or death due to any cause, whichever occurs first approximately up to 2 years
Secondary time to response (TTR) TTR:defined as time from the date of first administration to the date of first documented CR or PR approximately up to 2 years
Secondary evaluation of the immunogenicity of 7MW3711 Frequency and percentage of subjects with positive anti-drug antibody after being treated by 7MW3711. approximately up to 2 years
Secondary evaluation of the incidence of adverse events (AEs) (part 2) Incidence and seriousness of adverse events (AEs) and serious adverse events (SAEs) by CTCAE version 5.0. approximately up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Completed NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06365918 - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Phase 1
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2